# The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major

> **NCT02984475** · PHASE4 · UNKNOWN · sponsor: **Cairo University** · enrollment: 60 (estimated)

## Conditions studied

- Beta Thalassemia Major Anemia

## Interventions

- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02984475
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2018-12
- **Final completion:** 2019-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02984475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02984475, "The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02984475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*